LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia

LB Pharmaceuticals initiates patient dosing in phase 1 study of LB-102 for treatment of schizophrenia. (Credit: PublicDomainPictures from Pixabay)